Literature DB >> 6683733

The pathogenesis of Dupuytren's contracture: contractile mechanisms of the myofibroblasts.

M A Badalamente, L Stern, L C Hurst.   

Abstract

The role of myofibroblasts in the pathogenesis of Dupuytren's contracture was investigated by light and electron microscopic histochemical methods. Dupuytren's myofibroblasts contain an intracellular contractile mechanism that is driven by the dephosphorylation of adenosine triphosphate. Our study of calcium adenosinetriphosphatase (ATPase) activities verifies that the site of this energy system is on the myofilaments of the myofibroblasts. The degree of ATPase activity, as determined by cell counts, appeared to correlate with the residual contracture as predicted by the Legge and McFarlane Outcome Standard Formula. Further, alcian blue staining on the ultrastructural level indicates that the myofibroblasts are associated with each other and with surrounding collagen by a glycosaminoglycan matrix 300 to 1000 A thick. Collagen fibrils are attached by a similar matrix comprised of 100 A thick fibrils. The dynamic cellular architecture of the multiple adjacent myofibroblasts with their connections to surrounding collagen may be partially responsible for the residual clinical deformities seen in this disease.

Entities:  

Mesh:

Year:  1983        PMID: 6683733     DOI: 10.1016/s0363-5023(83)80150-6

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  8 in total

1.  Dupuytren's contracture studied with monoclonal antibodies to connective tissue differentiation antigens.

Authors:  A H Bartal; S Stahl; A Karev; C Lichtig
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

2.  The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease.

Authors:  Alexis Thomas; Ardeshir Bayat
Journal:  Ther Clin Risk Manag       Date:  2010-11-04       Impact factor: 2.423

3.  N-acetyl-L-cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren's disease by blunting TGF-beta signalling.

Authors:  Jürgen Kopp; Harun Seyhan; Bastian Müller; Johanna Lanczak; Elke Pausch; Axel M Gressner; Steven Dooley; R E Horch
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

4.  The Rationale for Treating the Nodule in Dupuytren's Disease.

Authors:  Lynn D Ketchum
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-01-08

Review 5.  Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances.

Authors:  David Warwick; José M Arandes-Renú; Giorgio Pajardi; Jörg Witthaut; Lawrence C Hurst
Journal:  J Plast Surg Hand Surg       Date:  2016-04-06

6.  Single cell force profiling of human myofibroblasts reveals a biophysical spectrum of cell states.

Authors:  Thomas B Layton; Lynn Williams; Huw Colin-York; Fiona E McCann; Marisa Cabrita; Marc Feldmann; Cameron Brown; Weilin Xie; Marco Fritzsche; Dominic Furniss; Jagdeep Nanchahal
Journal:  Biol Open       Date:  2020-03-24       Impact factor: 2.422

7.  Treatment of dupuytren disease with injectable collagenase in a veteran population: a case series at the department of veterans affairs new jersey health care system.

Authors:  Aditya Sood; Paul J Therattil; Angie M Paik; Mary F Simpson; Edward S Lee
Journal:  Eplasty       Date:  2014-03-27

Review 8.  Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren's contracture.

Authors:  C A Peimer; S Wilbrand; R A Gerber; D Chapman; P P Szczypa
Journal:  J Hand Surg Eur Vol       Date:  2014-04-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.